logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10610520 B1

PDFFull Text
Date of Patent:
Apr. 07, 2020

Filed:

Mar. 30, 2017

Heterocyclic compound

Applicant:

Takeda Pharmaceutical Company Limited, Chuo-ku, Osaka-shi, Osaka, JP;

Inventors:

Shuhei Ikeda, Kanagawa, JP;

Hideyuki Sugiyama, Kanagawa, JP;

Jumpei Aida, Kanagawa, JP;

Hidekazu Tokuhara, Kanagawa, JP;

Tomohiro Okawa, Kanagawa, JP;

Yuya Oguro, Kanagawa, JP;

Minoru Nakamura, Kanagawa, JP;

Masataka Murakami, Kanagawa, JP;

Assignee:

Takeda Pharmaceutical Company Limited, Osaka, JP;

Attorney:

Foley & Lardner LLP

Primary Examiner:

Timothy R Rozof

Int. Cl.
CPC ...
A61K 31/4188 (2006.01); A61P 21/00 (2006.01); A61P 25/28 (2006.01); A61P 25/24 (2006.01); A61P 25/08 (2006.01); A61K 31/407 (2006.01); A61K 31/4184 (2006.01); A61K 31/422 (2006.01); A61K 31/423 (2006.01); A61K 31/424 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/537 (2006.01); A61K 31/5386 (2006.01); C07D 487/10 (2006.01); C07D 498/10 (2006.01); C12N 9/18 (2006.01); A61P 25/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4188 (2013.01); A61K 31/407 (2013.01); A61K 31/4184 (2013.01); A61K 31/422 (2013.01); A61K 31/423 (2013.01); A61K 31/424 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/537 (2013.01); A61K 31/5386 (2013.01); A61P 21/00 (2018.01); A61P 25/08 (2018.01); A61P 25/16 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01); C07D 487/10 (2013.01); C07D 498/10 (2013.01); C12N 9/18 (2013.01);
Abstract

The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I):

Find Patent Forward Citations

Loading…